QUOTE AND NEWS
Motley Fool  Mar 23  Comment 
The Medicines Company is developing a new drug that could give Amgen's Repatha a run for its money in lowering bad cholesterol levels.
Motley Fool  Mar 17  Comment 
Shares of several biotech companies dropped after Amgen released important data from a long-term clinical trial that came up short of Wall Street's expectations.
newratings.com  Feb 6  Comment 
THOUSAND OAKS (dpa-AFX) - DBV Technologies' (DBVT) phase IIA investigator-initiated clinical trial of Viaskin Milk for the treatment of milk-induced Eosinophilic Esophagitis is now fully enrolled. In the study, dubbed SMILEE, 20 children...
Motley Fool  Feb 3  Comment 
Data from a competitor gives investors hope that the company's drug will have a larger potential market.




RELATED WIKI ARTICLES
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki